277 related articles for article (PubMed ID: 26607467)
1. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
El Batsh MM; El Batch MM; Shafik NM; Younos IH
Eur J Pharmacol; 2015 Dec; 769():297-305. PubMed ID: 26607467
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
Abdelsalam RM; Safar MM
J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913
[TBL] [Abstract][Full Text] [Related]
4. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
5. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
[TBL] [Abstract][Full Text] [Related]
6. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Pintana H; Apaijai N; Chattipakorn N; Chattipakorn SC
J Endocrinol; 2013 Jul; 218(1):1-11. PubMed ID: 23591914
[TBL] [Abstract][Full Text] [Related]
7. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Refaat R; Sakr A; Salama M; El Sarha A
Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857
[TBL] [Abstract][Full Text] [Related]
8. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Jin HY; Liu WJ; Park JH; Baek HS; Park TS
Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
10. The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity.
El-Sherbeeny NA; Nader MA
Can J Physiol Pharmacol; 2016 Mar; 94(3):251-6. PubMed ID: 26632647
[TBL] [Abstract][Full Text] [Related]
11. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S; Sole S
Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats.
Pintana H; Pongkan W; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
J Endocrinol; 2015 Aug; 226(2):M1-M11. PubMed ID: 26016746
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
[TBL] [Abstract][Full Text] [Related]
14. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X
PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231
[TBL] [Abstract][Full Text] [Related]
15. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
Akarte AS; Srinivasan BP; Gandhi S
Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G
J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837
[TBL] [Abstract][Full Text] [Related]
17. Effects of N-adamantyl-4-methylthiazol-2-amine on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.
Yang SJ; Je Lee W; Kim EA; Dal Nam K; Hahn HG; Young Choi S; Cho SW
Eur J Pharmacol; 2014 Aug; 736():26-34. PubMed ID: 24797782
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia.
Jain S; Sharma B
Physiol Behav; 2015 Dec; 152(Pt A):182-93. PubMed ID: 26382939
[TBL] [Abstract][Full Text] [Related]
19. Effects of 20-hydroxyecdysone on improving memory deficits in streptozotocin-induced type 1 diabetes mellitus in rat.
Xia X; Zhang Q; Liu R; Wang Z; Tang N; Liu F; Huang G; Jiang X; Gui G; Wang L; Sun X
Eur J Pharmacol; 2014 Oct; 740():45-52. PubMed ID: 24997424
[TBL] [Abstract][Full Text] [Related]
20. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.
Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M
Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
